A Novel Tumour-targeting Nanoliposome Drug Delivery System For The Treatment Of Malignant Gliomas
Funder
National Health and Medical Research Council
Funding Amount
$445,097.00
Summary
Most patients with malignant brain tumours die within a year after diagnosis due to the difficulty in effectively delivering drugs to the tumour cells. We aim to develop a safe and novel drug delivery system to effectively deliver anticancer drugs and novel anticancer agents to brain tumour cells that remain in normal brain after surgery. The success of this project will bring us a step forward in our efforts to significantly improve the survival rate and quality of life of such patients.
Understanding The Mechanisms Of Development And Treatment In Hydrocephalus.
Funder
National Health and Medical Research Council
Funding Amount
$395,914.00
Summary
This project aims to investigate the progressive change in cerebrospinal fluid dynamics, axonal damage and tissue mechanical properties during the development and treatment of hydrocephalus in-vivo. Results from this study is important to elucidate the mechanisms of hydrocephalus and to improve treatment and diagnosis of hydrocephalus.
Childhood Lymphatic Malformations: The Mechanism Of Rapamycin In Controlling Growth
Funder
National Health and Medical Research Council
Funding Amount
$456,579.00
Summary
Lymphatic malformations (also known as cystic hygromas or lymphangiomas) cause deformity and pain which can last lifelong. Current treatments help but do not fix all the symptoms. Rapamycin, a drug used for many years in children and adults with kidney transplants, may be useful for treating children with lymphatic malformations. We aim to understand how the drug works on the cells of lymphatic malformations in culture and in an animal model, to develop new and more effective treatments.
Refining Methods For Obtaining, Synthesising And Interpreting Research Evidence In Surgery
Funder
National Health and Medical Research Council
Funding Amount
$314,312.00
Summary
Research evidence plays a crucial role in improving clinical care. However the main forms of evidence and the tools that facilitate evidence use - namely randomised controlled trials (RCT) and structured systematic reviews of existing research - have had limited application in surgery for a variety of reasons. This project aims to promote the use of research evidence in surgical decision making by developing tools tailored to the predominance of non-RCTs in surgery and surgeons' information need ....Research evidence plays a crucial role in improving clinical care. However the main forms of evidence and the tools that facilitate evidence use - namely randomised controlled trials (RCT) and structured systematic reviews of existing research - have had limited application in surgery for a variety of reasons. This project aims to promote the use of research evidence in surgical decision making by developing tools tailored to the predominance of non-RCTs in surgery and surgeons' information needs.Read moreRead less
In this Fellowship I will capitalise on my role as Professor of Surgery and Public Health at Monash University, Director of the National Trauma Research Institute, and a surgeon at The Alfred Hospital, to lead a program of research that improves our understanding of what works in trauma care and trauma systems, uses scientific strategies to ensure research makes a difference to practice and policy, and supports further research that seeks to understand how research can best be used to improve in ....In this Fellowship I will capitalise on my role as Professor of Surgery and Public Health at Monash University, Director of the National Trauma Research Institute, and a surgeon at The Alfred Hospital, to lead a program of research that improves our understanding of what works in trauma care and trauma systems, uses scientific strategies to ensure research makes a difference to practice and policy, and supports further research that seeks to understand how research can best be used to improve injured peoples' lives.Read moreRead less
Until recently, cancer of the oesophagus was a very uncommon tumour in Australia and other western populations. However during the past three decades, there have been very large increases in the incidence of this disease. Indeed, rates of oesophageal cancer have risen faster than any other cancer in the United Statesand similar dramatic increases in incidence have been observed in Europe and Australia. With increasing population prevalence of the causes of cancer of the oesophagus in western soc ....Until recently, cancer of the oesophagus was a very uncommon tumour in Australia and other western populations. However during the past three decades, there have been very large increases in the incidence of this disease. Indeed, rates of oesophageal cancer have risen faster than any other cancer in the United Statesand similar dramatic increases in incidence have been observed in Europe and Australia. With increasing population prevalence of the causes of cancer of the oesophagus in western societies (namely acid reflux, obesity and poor diet), there are strong grounds for predicting that incidence will continue to rise, and that oesophageal cancer will constitute an increasingly large burden on society. Unfortunately, treatment options are limited, survival is often short, and there is no way of identifying which tumours will respond to therapy. This proposal will collect treatment and health outcomes data for a population-based cohort of patients with oesophageal cancer. The goal is to identify prognostic and predictive markers to aid patients and clinicians when making treatment decisions, as now exist for breast cancer. Such markers may also serve as novel targets for therapy. The proposed study builds upon the platform of the Australian Cancer Study [ACS], one of the world's largest studies of oesophageal cancer. This represents a unique opportunity to investigate a pressing clinical problem by building upon a study of acknowledged international importance.Read moreRead less
Molecular Mechanisms Of Tumour-associated Seizures
Funder
National Health and Medical Research Council
Funding Amount
$426,498.00
Summary
Seizures commonly develop in patients with brain tumours. Despite tumour resection, patients continue to experience seizures. Furthermore, patients can often be resistant to treatment with anti-epilepsy medications adding further burden to patient suffering, decreasing quality of life and overall survival. The cause is unknown and we propose identifiable causes are involved. This will provide effective targets for the development of medications for the treatment of these seizures.
Selective Therapies Targeting Tumour Vasculature Of Colorectal Liver Metastases
Funder
National Health and Medical Research Council
Funding Amount
$519,279.00
Summary
Cancer of the bowel is the second highest cause of cancer related deaths in Australia. Over 70% of these deaths are due to bowel cancer spread to the liver or liver metastases. Treatment options for the majority of patients with liver spread are limited. Although chemotherapies are a standard treatment option, they cause significant side-effects as they are small in size and thereby distributed to both cancer and normal tissue. Given the limitations of chemotherapy, our objective is to investiga ....Cancer of the bowel is the second highest cause of cancer related deaths in Australia. Over 70% of these deaths are due to bowel cancer spread to the liver or liver metastases. Treatment options for the majority of patients with liver spread are limited. Although chemotherapies are a standard treatment option, they cause significant side-effects as they are small in size and thereby distributed to both cancer and normal tissue. Given the limitations of chemotherapy, our objective is to investigate two new strategies which selectively destruct tumours with minimal effect to normal tissues. Cancer growth is dependent on an efficient blood supply. One strategy uses drug delivery systems (DDS) to selectively target cancers by exploiting the unique properties of tumour blood vessels. The second strategy uses vascular targeting agents (VTA's) which act on tumour vessels to reduce blood flow and starve the tumour of oxygen, leading to its destruction. We will be testing two agents: SMA-Pirarubicin, a DDS and an innovative VTA, Oxi4503, in an animal model of colorectal cancer liver metastases. Although these drugs are successful in destroying the majority of tumour cells, they have a patchy effect and do not completely destroy the cancerous growth. The varied effects of these agents may be due to variations in tissue hypoxia, tumour vessel structure or factors which trigger blood vessel formation and breakdown. These features will be investigated using techniques established within our laboratory. We will also investigate the combined effect of other novel agents and hyperbaric oxygen administration to improve the effectiveness of these drugs. A successful outcome will result in the development of an improved treatment method which targets tumours, producing maximum destruction with minimum side-effects. This has the potential to replace standard chemotherapies as the preferred treatment for patients with bowel cancer spread, with overall significant patient benefits.Read moreRead less